Teknova to Report Second Quarter 2023 Financial Results on August 10, 2023

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

HOLLISTER, Calif., July 26, 2023 (GLOBE NEWSWIRE) — Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2023, on Thursday, August 10, 2023, following the close of market.

Teknova will host a webcast and conference call on Thursday, August 10, 2023, beginning at 5:30 p.m. Eastern Time. Participants can access the live webcast on the Investor Relations section of the Teknova website and at this link: https://edge.media-server.com/mmc/p/uwatr9e7. To receive a PIN number for dial in, participants can register for the webcast via this link: https://register.vevent.com/register/BIb15ae1239db14699b0b6f88ed3ff392a. The webcast will be available for replay on the Company’s website approximately two hours after the event.

About Teknova   
Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel therapies that will help people live longer, healthier lives. Teknova offers fully customizable solutions for every stage of the workflow, supporting industry leaders in cell and gene therapy, molecular diagnostics, and synthetic biology. The Company’s fast turnaround of high-quality agar plates, microbial culture media, buffers and reagents, and water helps their customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 200,000 square feet of state-of-the-art facilities, Teknova’s modular manufacturing platform was designed by its team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of novel therapies. 

CONTACT: Investor Contacts 
Matt Lowell 
Chief Financial Officer 
matt.lowell@teknova.com
+1 831-637-1100 

Sara Michelmore 
MacDougall Advisors 
smichelmore@macdougall.bio 
+1 781-235-3060 

Media Contact 
Jennifer Henry  
Senior Vice President, Marketing 
jenn.henry@teknova.com  
+1 831-313-1259 

Staff

Recent Posts

Relief Therapeutics Advances Publication of 2025 Half-Year Report

GENEVA, SWITZERLAND / ACCESS Newswire / August 11, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY…

2 hours ago

HistoIndex Marks Another Step Forward with FibroSIGHT™ Plus: Introducing AI-based Quantitative Analysis in Fibrosis Assessment

SINGAPORE, Aug. 10, 2025 /PRNewswire/ -- HistoIndex, a pioneering leader in digital pathology solutions for…

5 hours ago

TERRY COLE FIX IT! DEA Blocks FDA Cannabis Trials While Contaminated Marijuana Floods State Markets

Terrance Cole's Choice: Reformer or Cover-Up Artist? New DEA Administrator Terrance Cole stands at a…

23 hours ago

Unlock the Power of MK-677: Your Guide to Buying MK-677 Ibutamoren Online

Buy MK-677 Ibutamoren capsules online to boost growth hormone and IGF-1 levels. Discover the benefits…

1 day ago

Top 6 Best Joint Supplements for Dogs to Support Canine Joint Health and Pain Relief

Discover the best joint supplement for dogs designed to promote joint health, reduce arthritis symptoms,…

1 day ago